INT114703

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.46
First Reported 2004
Last Reported 2010
Negated 1
Speculated 0
Reported most in Body
Documents 5
Total Number 7
Disease Relevance 4.25
Pain Relevance 0.24

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleoplasm (Wt1) RNA binding (Wt1) nucleus (Wt1)
intracellular (Wt1) DNA binding (Wt1) cytoplasm (Wt1)
Anatomy Link Frequency
fibroblast 1
T cell 1
Wt1 (Mus musculus)
Pain Link Frequency Relevance Heat
Inflammation 46 99.12 Very High Very High Very High
anesthesia 1 79.80 Quite High
agonist 10 74.08 Quite High
Inflammatory response 7 59.68 Quite High
cytokine 9 5.00 Very Low Very Low Very Low
Pain 7 5.00 Very Low Very Low Very Low
tolerance 4 5.00 Very Low Very Low Very Low
interstitial cystitis 4 5.00 Very Low Very Low Very Low
substance P 3 5.00 Very Low Very Low Very Low
Inflammatory stimuli 3 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Leukemia 32 99.96 Very High Very High Very High
Myeloid Leukemia 82 99.80 Very High Very High Very High
INFLAMMATION 58 99.12 Very High Very High Very High
Myelodysplastic Syndromes 21 98.52 Very High Very High Very High
Myelofibrosis 3 97.80 Very High Very High Very High
Wilms Tumor 2 97.44 Very High Very High Very High
Acquired Immune Deficiency Syndrome Or Hiv Infection 7 93.12 High High
Cancer 242 91.32 High High
Myocardial Infarction 7 91.16 High High
Chronic Myelomonocytic Leukemia 3 87.28 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Frequency of WT1 peptide/HLA-A*2402 tetramer+ cells
Positive_regulation (Frequency) of WT1
1) Confidence 0.46 Published 2010 Journal International Journal of Medical Sciences Section Body Doc Link PMC2860640 Disease Relevance 0.23 Pain Relevance 0
As to WT1 peptide vaccination for patients with leukemia, WT1 peptide vaccination for AML 20, 26, overt leukemia from MDS, and MDS with myelofibrosis 27 have been previously reported.
Positive_regulation (vaccination) of WT1 associated with leukemia, myeloid leukemia, myelodysplastic syndromes and myelofibrosis
2) Confidence 0.46 Published 2010 Journal International Journal of Medical Sciences Section Body Doc Link PMC2860640 Disease Relevance 1.16 Pain Relevance 0
Enrichment of co-purified mRNAs was not WT1(+KTS) dependent
Neg (not) Positive_regulation (dependent) of WT1
3) Confidence 0.45 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2714980 Disease Relevance 0.42 Pain Relevance 0
Northern blotting demonstrated a significant upregulation of syndecan-1, -2, -3, and -4, WT-1, fibronectin, and basic fibroblast growth factor (FGF) receptor 1.
Positive_regulation (upregulation) of WT-1 in fibroblast
4) Confidence 0.44 Published 2004 Journal Physiol. Genomics Section Abstract Doc Link 14625378 Disease Relevance 0.57 Pain Relevance 0.08
As to WT1 peptide vaccination for patients with leukemia, WT1 peptide vaccination for AML 20, 26, overt leukemia from MDS, and MDS with myelofibrosis 27 have been previously reported.
Positive_regulation (vaccination) of WT1 associated with leukemia, myeloid leukemia, myelodysplastic syndromes and myelofibrosis
5) Confidence 0.40 Published 2010 Journal International Journal of Medical Sciences Section Body Doc Link PMC2860640 Disease Relevance 1.13 Pain Relevance 0
In addition, inflammation associated with PAR2 stimulation led to an up-regulation of serpine 1, WT1, cyclin D1, IGF1R, and cathepsin K.


Positive_regulation (up-regulation) of WT1 associated with inflammation
6) Confidence 0.26 Published 2007 Journal BMC Immunol Section Body Doc Link PMC2000913 Disease Relevance 0.24 Pain Relevance 0.12
Two different protein-based vaccine approaches were able to induce a WT-1 specific HLA-A2 – restricted CD8+ T cell response, high levels of antigen specific IFN-?
Positive_regulation (induce) of WT-1 in T cell
7) Confidence 0.11 Published 2004 Journal J Transl Med Section Body Doc Link PMC441417 Disease Relevance 0.49 Pain Relevance 0.04

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox